CRISPR and Sickle Cell Disease (SCD)

In this clinical update, we bring you the latest news from four gene-editing trials sponsored by Beam Therapeutics, Intellia Therapeutics, Editas...

For the inaugural episode of CMN Live on 26th January 2024, we spoke with Eric Kmiec, Ph.D. about the successes of therapeutic gene editing to date,...

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

Caribou Biosciences gets closer to Phase 3 with its gene-edited cell therapy candidate for large B-cell lymphoma, and Editas Medicine reports positive...

Located in the ETH Innovation & Entrepreneurship Lab in Zürich (Switzerland), Ariya Bio's goal is to develop safe and effective gene-editing therapies...

This update shares news about recent designations awarded by the US FDA and European Medicines Agency for gene-editing candidates for the treatment of...

By decorating lipid nanoparticles with a cell-specific surface marker, researchers from the University of Pennsylvania were able to edit...

In this clinical trial roundup, we present an overview of the ongoing clinical trials involving base-editing therapeutic candidates. This article...